|
|
|
|
|
|
Tissue-Engineered Product for Bladder Reconstruction: The client asked Health Advances to investigate the market potential for its
tissue-engineered product in bladder augmentation and bladder reconstruction. The main indications for these procedures were neurogenic bladder
arising from spinal cord injury, multiple sclerosis or spina bifida, and bladder cancer. A pricing analysis was used to determine potential pricing,
including current economics for these procedures and associated complications from both the hospital and the payer perspectives. The Health Advances
team used several market examples to determine likely adoption rates for this type of product, including cadaveric fascia for pubovaginal sling and
InterStim for urge incontinence.
Radiopharmaceutical Diagnostic for Prostate Cancer: Health Advances determined the US commercial potential for a public company's novel
radiopharmaceutical used in the diagnosis and monitoring of prostate cancer. We used primary and secondary research to understand the current diagnostic
standard of care for prostate cancer, provide details on relevant patient segments, and determine the greatest unmet needs for each segment. We also
determined the potential penetration of the radiopharmaceutical into the diagnostic paradigm and developed detailed stacked incidence models of patient
segments and preliminary revenue projections.
Prostate Cancer: Health Advances studied the market for a currently marketed medical device to treat prostate cancer to determine how to
achieve broader market penetration. Our team assessed product positioning as a first-line alternative treatment versus a second-line therapy for treatment
failures. The study involved interviewing both current users and non-users to determine current perceptions of product positioning and use, and assessed
the opportunity for growth and the likely requirements for penetration (clinical trials, etc.) in other indications not yet targeted by the client.
Novel Dialysis Product: Health Advances conducted a system economics analysis for a novel product intended to treat dialysis patients. This product
would be used in conjunction with current continuous dialysis treatment to augment the performance of dialysis and more closely mimic the true functionality
of kidneys. The analysis was built on a large dataset obtained from a major health system. This provided detailed charge and reimbursement information on the
major cost drivers of managing dialysis patients and the costs when problems arise and they are hospitalized. Using inputs from physicians involved in the
development of the novel product, expected benefits were outlined and modeled into a range of economically justifiable prices to consider for the future
introduction. The specific price could be selected once trials were completed and the actual performance was documented.
|
|
 |
|
|
|
|
